Novo expands market cap on oral semaglutide data

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) added DKK20.4 billion ($3.2 billion) in market cap in Copenhagen on Thursday after reporting that oral diabetes candidate semaglutide was at least non-inferior to two approved therapies in reducing HbA1c and led to greater body weight reductions than both drugs in a pair of Phase IIIa trials to

Read the full 548 word article

User Sign In